Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study.
about
Identifying novel biomarkers for cardiovascular disease risk predictionLipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literatureLp-PLA2 Inhibition-The Atherosclerosis Panacea?Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study.Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study.Implication of lipoprotein associated phospholipase A2 activity in oxLDL uptake by macrophages.An effect of moderate hepatic impairment on the pharmacokinetics and safety of darapladib.Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese populationPericardial fat is associated with all-cause mortality but not incident CVD: the Rancho Bernardo Study.Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and AtherosclerosisTranslational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis.Lipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2Premature atherosclerosis in children with beta-thalassemia major: New diagnostic marker.The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease.Atherogenic Index of Plasma (AIP): A marker of cardiovascular diseaseClinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women.Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity, platelet-activating factor acetylhydrolase (PAF-AH) in leukocytes and body composition in healthy adults.Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target.Synergistic effects of colchicine combined with atorvastatin in rats with hyperlipidemia.From circulating biomarkers to genomics and imaging in the prediction of cardiovascular events in the general population.Inflammatory markers in coronary heart disease.Lipoprotein-associated phospholipase A2 (Lp-PLA2): a review of its role and significance as a cardiovascular biomarker.Critical appraisal of inflammatory markers in cardiovascular risk stratification.Novel biomarkers for cardiovascular risk assessment: current status and future directions.Proteomics Research in Cardiovascular Medicine and Biomarker Discovery.Performance characteristics of lipoprotein-associated phospholipase A2 activity assay on the Dimension Vista analyser and preliminary study of a healthy Italian population.Unraveling the PAF-AH/Lp-PLA2 controversy.Lipoprotein-Associated Phospholipase A2 and Risk of Carotid Atherosclerosis and Cardiovascular Events in Community-Based Older Adults in China.Associations between four types of single-nucleotide polymorphisms in PLA2G7 gene and clinical atherosclerosis: a meta-analysis.Association of lipoprotein-associated phospholipase A2 and risk of incident atrial fibrillation: Findings from 3 cohorts.Cardiovascular Risk Factors and Atherogenic Indices in an Iranian Population: Birjand East of Iran.Associations of platelet-activating factor acetylhydrolase (PAF-AH) gene polymorphisms with circulating PAF-AH levels and risk of coronary heart disease or blood stasis syndrome in the Chinese Han population.PPARgamma-2 and ADRB3 polymorphisms in connective tissue diseases and lipid disorders.
P2860
Q26865722-C07255FC-0C40-41BD-A7BD-2955AA0B1CA3Q33536648-264F3D69-960D-4641-83FD-BDF43AC00155Q33664272-F605A63F-9D5E-4B48-8025-303A2EE11900Q33755952-78E210D7-2E02-47BA-90AC-1D5BD25E9195Q33944562-84CFAD03-A2F7-471C-95C8-4BD11D3DA7E6Q33993219-A5B8D6F3-A89F-4FBE-977D-7EF04987D446Q34570879-353013BC-0954-4A17-B966-6AFD155EE44FQ35169770-3EFFC261-6E5A-495F-B58A-759FFA11ECDCQ35190926-638DB1D2-A223-48C8-BBC2-2776AAB74086Q35764402-BFBE1623-49B0-4C91-A9B9-893C1016E860Q35774358-9ADA18DA-C91F-4E1C-87A3-15DE98EC7913Q35856590-FBC4976E-8F52-4CC7-B6C1-799BE96BDEF1Q36145180-628AD3E4-0AF8-4074-BFFF-3E6FFA621B66Q36303189-702510CF-65A6-44D6-843A-5152369E94D0Q36399555-54FD77EB-6FD0-4D58-8CB0-47BBE1677868Q36469378-9BC508F0-5F6A-44EA-97A8-5368A7303ACAQ36752159-A1ABD6EF-5A84-44F9-9FE3-46C5B184EFB1Q37244962-2956C3C1-DA66-48CE-A309-347E9D41BB5FQ37445865-030CD931-2FF5-49F0-8E2E-1DCEF5C0D39AQ37733099-B7F6BC38-71A9-421B-801C-DBABB2CE070FQ37881966-4DB6EEF7-5A30-4BF8-B0C0-6FD997EC3FDAQ37947242-BD3192F2-9975-498E-AD3C-31E37C1CD300Q37991749-F62321CB-63D0-49A5-B62D-F40EC075249DQ38219501-F5CC74A6-B9F8-4B5C-B94E-4AC2F3B74EADQ38613760-C2A8D888-7E36-429A-AF6F-1523F914D587Q39050547-92C1F2A9-8E6B-4B0D-BA01-04EC7218554EQ42138491-3C06CFB9-5518-421D-9B29-F32C9088C9D9Q43204699-A300E9B8-69A3-4B23-8F53-77DF63412A0DQ47877808-444941EC-E281-4E1B-ADA4-2778BA5D138EQ49475562-78CD170E-AF48-42A4-8B07-D2CB146D7E63Q49972109-0211AC5F-589C-421C-B480-7F22D1C89230Q51745501-AC588CAA-9FF5-4E46-9226-22EC65C084BBQ54198588-41F18A01-906F-4D8D-8F80-70E39F0C8D1EQ55305262-0EC5546B-681A-4A47-AAC1-9A93CC7AFD54
P2860
Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study.
description
2008 nî lūn-bûn
@nan
2008 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մարտին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Lipoprotein-associated phospho ...... on: the Rancho Bernardo Study.
@ast
Lipoprotein-associated phospho ...... on: the Rancho Bernardo Study.
@en
Lipoprotein-associated phospho ...... on: the Rancho Bernardo Study.
@nl
type
label
Lipoprotein-associated phospho ...... on: the Rancho Bernardo Study.
@ast
Lipoprotein-associated phospho ...... on: the Rancho Bernardo Study.
@en
Lipoprotein-associated phospho ...... on: the Rancho Bernardo Study.
@nl
prefLabel
Lipoprotein-associated phospho ...... on: the Rancho Bernardo Study.
@ast
Lipoprotein-associated phospho ...... on: the Rancho Bernardo Study.
@en
Lipoprotein-associated phospho ...... on: the Rancho Bernardo Study.
@nl
P2093
P2860
P1476
Lipoprotein-associated phospho ...... on: the Rancho Bernardo Study.
@en
P2093
Gail A Laughlin
Lori B Daniels
Mark J Sarno
Ricki Bettencourt
Robert L Wolfert
P2860
P304
P356
10.1016/J.JACC.2007.10.048
P407
P577
2008-03-01T00:00:00Z